Boehringer Ingelheim

Clinical Study Synopsis for Public Disclosure

This clinical study synopsis is provided in line with **Boehringer Ingelheim's *Policy on Transparency and Publication of Clinical Study Data***.

The synopsis - which is part of the clinical study report - had been prepared in accordance with best practice and applicable legal and regulatory requirements at the time of study completion.

The synopsis may include approved and non-approved uses, doses, formulations, treatment regimens and/or age groups; it has not necessarily been submitted to regulatory authorities.

A synopsis is not intended to provide a comprehensive analysis of all data currently available regarding a particular drug. More current information regarding a drug is available in the approved labeling information which may vary from country to country..

Additional information on this study and the drug concerned may be provided upon request based on **Boehringer Ingelheim's Policy on Transparency and Publication of Clinical Study Data**.

Name of company: Boehringer Ingelheim International GmbH		**Statement**	Boehringer Ingelheim
Name of finished product: n.a.			
Name of active ingredient: BI 1034020		**Page:** 1	
Report date:	**Trial-Number:** 1312.1	**Study period (dates):** LPO: 28 Apr 2014	

Title of study:	Safety, tolerability, pharmacokinetics and pharmacodynamics of single rising intravenous and subcutaneous doses of BI 1034020 in healthy male volunteers (partially randomised, single-blind, placebo-controlled within dose groups, clinical phase I study)
Coordinating Investigator:	[redacted]
Study center(s):	Human Pharmacology Centre, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/Ingelheim, Germany
Publication (reference):	None
Clinical phase:	I
Statement on discontinuation of the study:	Due to a serious adverse event the study was discontinued prematurely